{
    "id": 24971,
    "fullName": "EGFR - PURB",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR-PURB results from the fusion of EGFR and PURB (PMID: 27102076). EGFR-PURB has been identified in lung adenocarcinoma (PMID: 27102076), but has not been biochemically characterized and therefore, the effect on fusion protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "EGFR - PURB",
    "createDate": "08/01/2016",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5814,
                "geneSymbol": "PURB",
                "terms": [
                    "PURB",
                    "PURBETA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 7539,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR-PURB demonstrated a partial response when treated with Tarceva (erlotinib), resulting in a 48% decrease in lesion size and ongoing therapy for 20 months without indication of progression (PMID: 27102076).",
            "molecularProfile": {
                "id": 25738,
                "profileName": "EGFR - PURB"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6404,
                    "pubMedId": 27102076,
                    "title": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25738,
            "profileName": "EGFR - PURB",
            "profileTreatmentApproaches": [
                {
                    "id": 10506,
                    "name": "Erlotinib",
                    "profileName": "EGFR - PURB"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}